Is DMAC or INBX more profitable?

DiaMedica Therapeutics' return on equity of -77.15% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.15% -69.23% Inhibrx Biosciences N/A -563.90% -72.32%

Which has better valuation and earnings, DMAC or AVLN?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A Avalyn Pharma N/A N/A N/A -$21.83 N/A

Is DMAC or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.15% -69.23% Avalyn Pharma N/A N/A N/A

DiaMedica Therapeutics (DMAC) Competitors

$7.62 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$7.66 +0.04 (+0.52%)

As of 07/2/2026 07:55 PM Eastern

Compare

DMAC vs. INBX, ARDX, AVLN, XERS, and PAHC

Should you buy DiaMedica Therapeutics stock or one of its competitors? MarketBeat compares DiaMedica Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DiaMedica Therapeutics include Inhibrx Biosciences (INBX), Ardelyx (ARDX), Avalyn Pharma (AVLN), Xeris Biopharma (XERS), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

How does DiaMedica Therapeutics compare to Inhibrx Biosciences?

DiaMedica Therapeutics (NASDAQ:DMAC) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

DiaMedica Therapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Inhibrx Biosciences	$1.30M	1,101.15	-$140.05M	-$8.39	N/A

In the previous week, DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
Inhibrx Biosciences	Neutral

DiaMedica Therapeutics' return on equity of -77.15% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

DiaMedica Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 61.85%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 53.72%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, meaning that its share price is 241% more volatile than the broader market.

Summary

DiaMedica Therapeutics beats Inhibrx Biosciences on 8 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Ardelyx?

DiaMedica Therapeutics (NASDAQ:DMAC) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

DiaMedica Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Ardelyx	-13.58%	-38.11%	-11.85%

DiaMedica Therapeutics currently has a consensus target price of $12.33, suggesting a potential upside of 61.85%. Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 198.43%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

DiaMedica Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Ardelyx	$427.68M	3.04	-$61.60M	-$0.23	N/A

In the previous week, Ardelyx had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 1 mentions for Ardelyx and 0 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Ardelyx'saverage media sentiment score.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
Ardelyx	Neutral

Summary

Ardelyx beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Avalyn Pharma?

DiaMedica Therapeutics (NASDAQ:DMAC) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Avalyn Pharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Avalyn Pharma	N/A	N/A	N/A

DiaMedica Therapeutics currently has a consensus price target of $12.33, indicating a potential upside of 61.85%. Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 98.45%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Avalyn Pharma'saverage media sentiment score.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
Avalyn Pharma	Neutral

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Summary

Avalyn Pharma beats DiaMedica Therapeutics on 6 of the 10 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Xeris Biopharma?

DiaMedica Therapeutics (NASDAQ:DMAC) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

DiaMedica Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 61.85%. Xeris Biopharma has a consensus target price of $10.80, indicating a potential upside of 30.43%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe DiaMedica Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 10 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 10 mentions for Xeris Biopharma and 0 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 beat Xeris Biopharma's score of -0.12 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
Xeris Biopharma	Neutral

Xeris Biopharma has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Xeris Biopharma	$314.85M	4.54	$550K	$0.06	138.00

DiaMedica Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to DiaMedica Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Xeris Biopharma	3.81%	735.00%	3.24%

Summary

Xeris Biopharma beats DiaMedica Therapeutics on 9 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Phibro Animal Health?

DiaMedica Therapeutics (NASDAQ:DMAC) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Phibro Animal Health has a net margin of 6.35% compared to DiaMedica Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Phibro Animal Health had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Phibro Animal Health and 0 mentions for DiaMedica Therapeutics. Phibro Animal Health's average media sentiment score of 0.44 beat DiaMedica Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
Phibro Animal Health	Neutral

Phibro Animal Health has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Phibro Animal Health	$1.50B	0.90	$48.26M	$2.33	14.27

DiaMedica Therapeutics presently has a consensus price target of $12.33, suggesting a potential upside of 61.85%. Phibro Animal Health has a consensus price target of $42.50, suggesting a potential upside of 27.78%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe DiaMedica Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

DiaMedica Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Summary

Phibro Animal Health beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$410.59M	$3.78B	$7.17B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-10.73	21.61	28.02	24.70
Price / Sales	N/A	342.06	540.72	98.05
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	7.06	8.66	10.96	6.46
Net Income	-$32.77M	$23.81M	$3.57B	$337.01M
7 Day Performance	16.34%	3.39%	2.12%	1.69%
1 Month Performance	35.11%	10.81%	5.25%	3.81%
1 Year Performance	108.77%	62.61%	33.29%	23.90%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.3472 of 5 stars	$7.62 flat	$12.33 +61.9%	+108.8%	$410.59M	N/A	N/A	20	Gap Down
INBX Inhibrx Biosciences	1.9238 of 5 stars	$94.81 -0.5%	$150.00 +58.2%	+499.2%	$1.39B	$1.30M	N/A	166	High Trading Volume
ARDX Ardelyx	2.1595 of 5 stars	$5.54 -8.7%	$15.73 +184.1%	+22.7%	$1.37B	$407.32M	N/A	90	High Trading Volume
AVLN Avalyn Pharma	3.6127 of 5 stars	$30.71 +6.0%	$59.00 +92.1%	N/A	$1.36B	N/A	N/A	51	High Trading Volume
XERS Xeris Biopharma	3.0869 of 5 stars	$7.69 +3.9%	$10.80 +40.4%	+74.1%	$1.33B	$291.85M	128.17	290	News Coverage Insider Trade Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. INBX, ARDX, AVLN, XERS, and PAHC

How does DiaMedica Therapeutics compare to Inhibrx Biosciences?

Summary

How does DiaMedica Therapeutics compare to Ardelyx?

Summary

How does DiaMedica Therapeutics compare to Avalyn Pharma?

Summary

How does DiaMedica Therapeutics compare to Xeris Biopharma?

Summary

How does DiaMedica Therapeutics compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. INBX, ARDX, AVLN, XERS, and PAHC

How does DiaMedica Therapeutics compare to Inhibrx Biosciences?

Which has preferable valuation and earnings, DMAC or INBX?

Does the media prefer DMAC or INBX?

Is DMAC or INBX more profitable?

Do analysts recommend DMAC or INBX?

Do insiders and institutionals believe in DMAC or INBX?

Which has more risk & volatility, DMAC or INBX?

Summary

How does DiaMedica Therapeutics compare to Ardelyx?

Is DMAC or ARDX more profitable?

Do analysts rate DMAC or ARDX?

Do insiders and institutionals hold more shares of DMAC or ARDX?

Which has more volatility and risk, DMAC or ARDX?

Which has preferable earnings & valuation, DMAC or ARDX?

Does the media refer more to DMAC or ARDX?

Summary

How does DiaMedica Therapeutics compare to Avalyn Pharma?

Is DMAC or AVLN more profitable?

Do analysts rate DMAC or AVLN?

Does the media prefer DMAC or AVLN?

Do institutionals and insiders believe in DMAC or AVLN?

Which has better valuation and earnings, DMAC or AVLN?

Summary

How does DiaMedica Therapeutics compare to Xeris Biopharma?

Do analysts rate DMAC or XERS?

Do institutionals & insiders believe in DMAC or XERS?

Does the media prefer DMAC or XERS?

Which has stronger earnings and valuation, DMAC or XERS?

Which has more volatility & risk, DMAC or XERS?

Is DMAC or XERS more profitable?

Summary

How does DiaMedica Therapeutics compare to Phibro Animal Health?

Is DMAC or PAHC more profitable?

Does the media prefer DMAC or PAHC?

Which has stronger earnings and valuation, DMAC or PAHC?

Do analysts recommend DMAC or PAHC?

Do institutionals & insiders believe in DMAC or PAHC?

Which has more volatility & risk, DMAC or PAHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools